Individuals are given three vaccinations at the 18 month National Immunisation Program schedule point:

  • Priorix-tetra or ProQuad protects against measles, mumps, rubella and chickenpox
  • Infanrix or Tripacel protects against Diphtheria, tetanus and whooping cough
  • Act-HIB protects against Haemophilus influenzae type b

AusVaxSafety has been conducting surveillance of the vaccines given at the 18 month schedule point on a continuous basis since 2019. The analysis has remained constant over this time and not identified any safety concerns.

The latest medical attendance rate for the 18 month schedule point is below and will be updated on a quarterly basis.

In April 2022, the vaccine safety survey used for active surveillance of vaccines on the National Immunisation Program was updated to replicate the vaccine safety survey used for COVID-19 and seasonal influenza vaccine surveillance to allow for better comparison across all vaccines monitored. Data displayed on this page show analysis of the new survey. Reassuringly, data from the new vaccine safety survey are comparable to the rates reported in the previous survey.

More detailed safety data from the 18 month schedule point is available from the 2022 Vaccine Safety in Australia AusVaxSafety Summary Report below.

Access AusVaxSafety data from the 18 month schedule point for 2022

Last updated March 2024